The clinical application value of serum hs-CRP, IL-1β and Lp-PLA2 in ACS

Objective To investigate the serum levels of high sensitivity C-reactive protein (hs-CRP), interleukin-1β (IL-1β) and lipoprotein-associated phospholipase A2 (Lp-PLA2), and investigate their clinical diagnostic value in acute coronary syndrome (ACS) patients. Methods Fifty three clinical serum samples of patients specifically diagnosed with acute coronary syndrome were collected. A total of 21 healthy subjects were enrolled as healthy controls. Serum IL-1β and Lp-PLA2 levels were determined by enzyme-linked immunosorbent assay. The concentration of hs-CRP was tested by immunoturbidimetry method. Results Compared to the healthy controls, the levels of serum hs-CRP, IL-1βand Lp-PLA2 were significantly higher in ACS and ACS subgroups (P<0.05), respectively. The level of Lp-PLA2 was gradually increased among healthy controls, angina pectoris (AP), ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) groups. The best cut-off value of hs-CRP, IL-1β and Lp-PLA2 was 7.44 mg/L, 90.88 ng/L and 219.92 μg/L, respectively. The parallel test had better sensitivity (94.3%) and specificity (100%). Conclusions Serum hs-CRP, IL-1β and Lp-PLA2 play an important role in classifying the clinical types and monitoring the conditions of patients with ACS. Combination of hs-CRP, IL-1β and Lp-PLA2 is expected to be a new biomarker for ACS. Key words: Coronary artery disease/ME/DI; C-reactive protein/ME; Interleukin-1beta/; Phospholipases A2/ME; Lipoproteins/ME